RxDoctor Payments Data

Timothy Bichler, MD

Pulmonary Disease · Phoenix, AZNPI 1477518041

Payments from drug & device makers

$6,725in general payments, 2019–2025

Across 340 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$675
  • Medwest Associates$579
  • Sanofi$464
  • Boehringer Ingelheim$457
  • Mallinckrodt Hospital Products Inc.$286
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,14291%
  • Education$5849%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,725 in reported general payments places this provider in the 60th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$248,781
Medicare patients
547
Services billed
2,277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter539$438,654
OfevNintedanib Esylate25$301,455
OpsumitMacitentan13$166,709
Breo ElliptaFluticasone/Vilanterol147$91,554
Breztri AerosphereBudesonide/Glycopyr/Formoterol116$86,667
Spiriva RespimatTiotropium Bromide110$68,786
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr114$68,773
XolairOmalizumab34$67,902
Spiriva HandihalerTiotropium Bromide48$34,990
SymbicortBudesonide/Formoterol Fumarate106$29,438
Stiolto RespimatTiotropium Br/Olodaterol Hcl51$28,695
Advair HfaFluticasone Propion/Salmeterol43$18,660
Fluticasone-SalmeterolFluticasone Propion/Salmeterol69$14,888
Incruse ElliptaUmeclidinium Bromide29$13,264
Albuterol Sulfate HfaAlbuterol Sulfate396$10,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,017$615,021842 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$457$398,936186 claims
Actelion Pharmaceuticals US, Inc.Opsumit$128$166,70913 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$675$122,565236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 250 pulmonary disease providers in Arizona.

Other pulmonary disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →